The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease.
Identifieur interne : 000F73 ( PubMed/Corpus ); précédent : 000F72; suivant : 000F74The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease.
Auteurs : Klaus Seppi ; Daniel Weintraub ; Miguel Coelho ; Santiago Perez-Lloret ; Susan H. Fox ; Regina Katzenschlager ; Eva-Maria Hametner ; Werner Poewe ; Olivier Rascol ; Christopher G. Goetz ; Cristina SampaioSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2011.
English descriptors
- KwdEn :
- Antiparkinson Agents (therapeutic use), Autonomic Nervous System Diseases (drug therapy), Autonomic Nervous System Diseases (etiology), Cognition Disorders (drug therapy), Cognition Disorders (etiology), Evidence-Based Medicine, Humans, Mental Disorders (drug therapy), Mental Disorders (etiology), Mood Disorders (drug therapy), Mood Disorders (etiology), Parkinson Disease (drug therapy), Parkinson Disease (psychology), Parkinson Disease (therapy), Psychotropic Drugs (therapeutic use), Randomized Controlled Trials as Topic, Sleep Disorders, Intrinsic (drug therapy), Sleep Disorders, Intrinsic (etiology), Treatment Outcome.
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Psychotropic Drugs.
- drug therapy : Autonomic Nervous System Diseases, Cognition Disorders, Mental Disorders, Mood Disorders, Parkinson Disease, Sleep Disorders, Intrinsic.
- etiology : Autonomic Nervous System Diseases, Cognition Disorders, Mental Disorders, Mood Disorders, Sleep Disorders, Intrinsic.
- psychology : Parkinson Disease.
- therapy : Parkinson Disease.
- Evidence-Based Medicine, Humans, Randomized Controlled Trials as Topic, Treatment Outcome.
Abstract
The Movement Disorder Society (MDS) Task Force on Evidence-Based Medicine (EBM) Review of Treatments for Parkinson's Disease (PD) was first published in 2002 and was updated in 2005 to cover clinical trial data up to January 2004 with the focus on motor symptoms of PD. In this revised version the MDS task force decided it was necessary to extend the review to non-motor symptoms. The objective of this work was to update previous EBM reviews on treatments for PD with a focus on non-motor symptoms. Level-I (randomized controlled trial, RCT) reports of pharmacological and nonpharmacological interventions for the non-motor symptoms of PD, published as full articles in English between January 2002 and December 2010 were reviewed. Criteria for inclusion and ranking followed the original program outline and adhered to EBM methodology. For efficacy conclusions, treatments were designated: efficacious, likely efficacious, unlikely efficacious, non-efficacious, or insufficient evidence. Safety data were catalogued and reviewed. Based on the combined efficacy and safety assessment, Implications for clinical practice were determined using the following designations: clinically useful, possibly useful, investigational, unlikely useful, and not useful. Fifty-four new studies qualified for efficacy review while several other studies covered safety issues. Updated and new efficacy conclusions were made for all indications. The treatments that are efficacious for the management of the different non-motor symptoms are as follows: pramipexole for the treatment of depressive symptoms, clozapine for the treatment of psychosis, rivastigmine for the treatment of dementia, and botulinum toxin A (BTX-A) and BTX-B as well as glycopyrrolate for the treatment of sialorrhea. The practical implications for these treatments, except for glycopyrrolate, are that they are clinically useful. Since there is insufficient evidence of glycopyrrolate for the treatment of sialorrhea exceeding 1 week, the practice implication is that it is possibly useful. The treatments that are likely efficacious for the management of the different non-motor symptoms are as follows: the tricyclic antidepressants nortriptyline and desipramine for the treatment of depression or depressive symptoms and macrogol for the treatment of constipation. The practice implications for these treatments are possibly useful. For most of the other interventions there is insufficient evidence to make adequate conclusions on their efficacy. This includes the tricyclic antidepressant amitriptyline, all selective serotonin reuptake inhibitors (SSRIs) reviewed (paroxetine, citalopram, sertraline, and fluoxetine), the newer antidepressants atomoxetine and nefazodone, pergolide, Ω-3 fatty acids as well as repetitive transcranial magnetic stimulation (rTMS) for the treatment of depression or depressive symptoms; methylphenidate and modafinil for the treatment of fatigue; amantadine for the treatment of pathological gambling; donepezil, galantamine, and memantine for the treatment of dementia; quetiapine for the treatment of psychosis; fludrocortisone and domperidone for the treatment of orthostatic hypotension; sildenafil for the treatment of erectile dysfunction, ipratropium bromide spray for the treatment of sialorrhea; levodopa/carbidopa controlled release (CR), pergolide, eszopiclone, melatonin 3 to 5 mg and melatonin 50 mg for the treatment of insomnia and modafinil for the treatment of excessive daytime sleepiness. Due to safety issues the practice implication is that pergolide and nefazodone are not useful for the above-mentioned indications. Due to safety issues, olanzapine remains not useful for the treatment of psychosis. As none of the studies exceeded a duration of 6 months, the recommendations given are for the short-term management of the different non-motor symptoms. There were no RCTs that met inclusion criteria for the treatment of anxiety disorders, apathy, medication-related impulse control disorders and related behaviors other than pathological gambling, rapid eye movement (REM) sleep behavior disorder (RBD), sweating, or urinary dysfunction. Therefore, there is insufficient evidence for the treatment of these indications. This EBM review of interventions for the non-motor symptoms of PD updates the field, but, because several RCTs are ongoing, a continual updating process is needed. Several interventions and indications still lack good quality evidence, and these gaps offer an opportunity for ongoing research. © 2011 Movement Disorder Society.
DOI: 10.1002/mds.23884
PubMed: 22021174
Links to Exploration step
pubmed:22021174Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease.</title>
<author><name sortKey="Seppi, Klaus" sort="Seppi, Klaus" uniqKey="Seppi K" first="Klaus" last="Seppi">Klaus Seppi</name>
<affiliation><nlm:affiliation>Department of Neurology, Medical University Innsbruck, Innsbruck, Austria. klaus.seppi@uki.at</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name>
</author>
<author><name sortKey="Coelho, Miguel" sort="Coelho, Miguel" uniqKey="Coelho M" first="Miguel" last="Coelho">Miguel Coelho</name>
</author>
<author><name sortKey="Perez Lloret, Santiago" sort="Perez Lloret, Santiago" uniqKey="Perez Lloret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name>
</author>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H" last="Fox">Susan H. Fox</name>
</author>
<author><name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name>
</author>
<author><name sortKey="Hametner, Eva Maria" sort="Hametner, Eva Maria" uniqKey="Hametner E" first="Eva-Maria" last="Hametner">Eva-Maria Hametner</name>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
</author>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G" last="Goetz">Christopher G. Goetz</name>
</author>
<author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2011">2011</date>
<idno type="doi">10.1002/mds.23884</idno>
<idno type="RBID">pubmed:22021174</idno>
<idno type="pmid">22021174</idno>
<idno type="wicri:Area/PubMed/Corpus">000F73</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease.</title>
<author><name sortKey="Seppi, Klaus" sort="Seppi, Klaus" uniqKey="Seppi K" first="Klaus" last="Seppi">Klaus Seppi</name>
<affiliation><nlm:affiliation>Department of Neurology, Medical University Innsbruck, Innsbruck, Austria. klaus.seppi@uki.at</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name>
</author>
<author><name sortKey="Coelho, Miguel" sort="Coelho, Miguel" uniqKey="Coelho M" first="Miguel" last="Coelho">Miguel Coelho</name>
</author>
<author><name sortKey="Perez Lloret, Santiago" sort="Perez Lloret, Santiago" uniqKey="Perez Lloret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name>
</author>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H" last="Fox">Susan H. Fox</name>
</author>
<author><name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name>
</author>
<author><name sortKey="Hametner, Eva Maria" sort="Hametner, Eva Maria" uniqKey="Hametner E" first="Eva-Maria" last="Hametner">Eva-Maria Hametner</name>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
</author>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G" last="Goetz">Christopher G. Goetz</name>
</author>
<author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2011" type="published">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (therapeutic use)</term>
<term>Autonomic Nervous System Diseases (drug therapy)</term>
<term>Autonomic Nervous System Diseases (etiology)</term>
<term>Cognition Disorders (drug therapy)</term>
<term>Cognition Disorders (etiology)</term>
<term>Evidence-Based Medicine</term>
<term>Humans</term>
<term>Mental Disorders (drug therapy)</term>
<term>Mental Disorders (etiology)</term>
<term>Mood Disorders (drug therapy)</term>
<term>Mood Disorders (etiology)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (psychology)</term>
<term>Parkinson Disease (therapy)</term>
<term>Psychotropic Drugs (therapeutic use)</term>
<term>Randomized Controlled Trials as Topic</term>
<term>Sleep Disorders, Intrinsic (drug therapy)</term>
<term>Sleep Disorders, Intrinsic (etiology)</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Psychotropic Drugs</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Autonomic Nervous System Diseases</term>
<term>Cognition Disorders</term>
<term>Mental Disorders</term>
<term>Mood Disorders</term>
<term>Parkinson Disease</term>
<term>Sleep Disorders, Intrinsic</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Autonomic Nervous System Diseases</term>
<term>Cognition Disorders</term>
<term>Mental Disorders</term>
<term>Mood Disorders</term>
<term>Sleep Disorders, Intrinsic</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Evidence-Based Medicine</term>
<term>Humans</term>
<term>Randomized Controlled Trials as Topic</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The Movement Disorder Society (MDS) Task Force on Evidence-Based Medicine (EBM) Review of Treatments for Parkinson's Disease (PD) was first published in 2002 and was updated in 2005 to cover clinical trial data up to January 2004 with the focus on motor symptoms of PD. In this revised version the MDS task force decided it was necessary to extend the review to non-motor symptoms. The objective of this work was to update previous EBM reviews on treatments for PD with a focus on non-motor symptoms. Level-I (randomized controlled trial, RCT) reports of pharmacological and nonpharmacological interventions for the non-motor symptoms of PD, published as full articles in English between January 2002 and December 2010 were reviewed. Criteria for inclusion and ranking followed the original program outline and adhered to EBM methodology. For efficacy conclusions, treatments were designated: efficacious, likely efficacious, unlikely efficacious, non-efficacious, or insufficient evidence. Safety data were catalogued and reviewed. Based on the combined efficacy and safety assessment, Implications for clinical practice were determined using the following designations: clinically useful, possibly useful, investigational, unlikely useful, and not useful. Fifty-four new studies qualified for efficacy review while several other studies covered safety issues. Updated and new efficacy conclusions were made for all indications. The treatments that are efficacious for the management of the different non-motor symptoms are as follows: pramipexole for the treatment of depressive symptoms, clozapine for the treatment of psychosis, rivastigmine for the treatment of dementia, and botulinum toxin A (BTX-A) and BTX-B as well as glycopyrrolate for the treatment of sialorrhea. The practical implications for these treatments, except for glycopyrrolate, are that they are clinically useful. Since there is insufficient evidence of glycopyrrolate for the treatment of sialorrhea exceeding 1 week, the practice implication is that it is possibly useful. The treatments that are likely efficacious for the management of the different non-motor symptoms are as follows: the tricyclic antidepressants nortriptyline and desipramine for the treatment of depression or depressive symptoms and macrogol for the treatment of constipation. The practice implications for these treatments are possibly useful. For most of the other interventions there is insufficient evidence to make adequate conclusions on their efficacy. This includes the tricyclic antidepressant amitriptyline, all selective serotonin reuptake inhibitors (SSRIs) reviewed (paroxetine, citalopram, sertraline, and fluoxetine), the newer antidepressants atomoxetine and nefazodone, pergolide, Ω-3 fatty acids as well as repetitive transcranial magnetic stimulation (rTMS) for the treatment of depression or depressive symptoms; methylphenidate and modafinil for the treatment of fatigue; amantadine for the treatment of pathological gambling; donepezil, galantamine, and memantine for the treatment of dementia; quetiapine for the treatment of psychosis; fludrocortisone and domperidone for the treatment of orthostatic hypotension; sildenafil for the treatment of erectile dysfunction, ipratropium bromide spray for the treatment of sialorrhea; levodopa/carbidopa controlled release (CR), pergolide, eszopiclone, melatonin 3 to 5 mg and melatonin 50 mg for the treatment of insomnia and modafinil for the treatment of excessive daytime sleepiness. Due to safety issues the practice implication is that pergolide and nefazodone are not useful for the above-mentioned indications. Due to safety issues, olanzapine remains not useful for the treatment of psychosis. As none of the studies exceeded a duration of 6 months, the recommendations given are for the short-term management of the different non-motor symptoms. There were no RCTs that met inclusion criteria for the treatment of anxiety disorders, apathy, medication-related impulse control disorders and related behaviors other than pathological gambling, rapid eye movement (REM) sleep behavior disorder (RBD), sweating, or urinary dysfunction. Therefore, there is insufficient evidence for the treatment of these indications. This EBM review of interventions for the non-motor symptoms of PD updates the field, but, because several RCTs are ongoing, a continual updating process is needed. Several interventions and indications still lack good quality evidence, and these gaps offer an opportunity for ongoing research. © 2011 Movement Disorder Society.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">22021174</PMID>
<DateCreated><Year>2011</Year>
<Month>10</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted><Year>2012</Year>
<Month>02</Month>
<Day>27</Day>
</DateCompleted>
<DateRevised><Year>2014</Year>
<Month>10</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>26 Suppl 3</Volume>
<PubDate><Year>2011</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease.</ArticleTitle>
<Pagination><MedlinePgn>S42-80</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.23884</ELocationID>
<Abstract><AbstractText>The Movement Disorder Society (MDS) Task Force on Evidence-Based Medicine (EBM) Review of Treatments for Parkinson's Disease (PD) was first published in 2002 and was updated in 2005 to cover clinical trial data up to January 2004 with the focus on motor symptoms of PD. In this revised version the MDS task force decided it was necessary to extend the review to non-motor symptoms. The objective of this work was to update previous EBM reviews on treatments for PD with a focus on non-motor symptoms. Level-I (randomized controlled trial, RCT) reports of pharmacological and nonpharmacological interventions for the non-motor symptoms of PD, published as full articles in English between January 2002 and December 2010 were reviewed. Criteria for inclusion and ranking followed the original program outline and adhered to EBM methodology. For efficacy conclusions, treatments were designated: efficacious, likely efficacious, unlikely efficacious, non-efficacious, or insufficient evidence. Safety data were catalogued and reviewed. Based on the combined efficacy and safety assessment, Implications for clinical practice were determined using the following designations: clinically useful, possibly useful, investigational, unlikely useful, and not useful. Fifty-four new studies qualified for efficacy review while several other studies covered safety issues. Updated and new efficacy conclusions were made for all indications. The treatments that are efficacious for the management of the different non-motor symptoms are as follows: pramipexole for the treatment of depressive symptoms, clozapine for the treatment of psychosis, rivastigmine for the treatment of dementia, and botulinum toxin A (BTX-A) and BTX-B as well as glycopyrrolate for the treatment of sialorrhea. The practical implications for these treatments, except for glycopyrrolate, are that they are clinically useful. Since there is insufficient evidence of glycopyrrolate for the treatment of sialorrhea exceeding 1 week, the practice implication is that it is possibly useful. The treatments that are likely efficacious for the management of the different non-motor symptoms are as follows: the tricyclic antidepressants nortriptyline and desipramine for the treatment of depression or depressive symptoms and macrogol for the treatment of constipation. The practice implications for these treatments are possibly useful. For most of the other interventions there is insufficient evidence to make adequate conclusions on their efficacy. This includes the tricyclic antidepressant amitriptyline, all selective serotonin reuptake inhibitors (SSRIs) reviewed (paroxetine, citalopram, sertraline, and fluoxetine), the newer antidepressants atomoxetine and nefazodone, pergolide, Ω-3 fatty acids as well as repetitive transcranial magnetic stimulation (rTMS) for the treatment of depression or depressive symptoms; methylphenidate and modafinil for the treatment of fatigue; amantadine for the treatment of pathological gambling; donepezil, galantamine, and memantine for the treatment of dementia; quetiapine for the treatment of psychosis; fludrocortisone and domperidone for the treatment of orthostatic hypotension; sildenafil for the treatment of erectile dysfunction, ipratropium bromide spray for the treatment of sialorrhea; levodopa/carbidopa controlled release (CR), pergolide, eszopiclone, melatonin 3 to 5 mg and melatonin 50 mg for the treatment of insomnia and modafinil for the treatment of excessive daytime sleepiness. Due to safety issues the practice implication is that pergolide and nefazodone are not useful for the above-mentioned indications. Due to safety issues, olanzapine remains not useful for the treatment of psychosis. As none of the studies exceeded a duration of 6 months, the recommendations given are for the short-term management of the different non-motor symptoms. There were no RCTs that met inclusion criteria for the treatment of anxiety disorders, apathy, medication-related impulse control disorders and related behaviors other than pathological gambling, rapid eye movement (REM) sleep behavior disorder (RBD), sweating, or urinary dysfunction. Therefore, there is insufficient evidence for the treatment of these indications. This EBM review of interventions for the non-motor symptoms of PD updates the field, but, because several RCTs are ongoing, a continual updating process is needed. Several interventions and indications still lack good quality evidence, and these gaps offer an opportunity for ongoing research. © 2011 Movement Disorder Society.</AbstractText>
<CopyrightInformation>Copyright © 2011 Movement Disorder Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Seppi</LastName>
<ForeName>Klaus</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Department of Neurology, Medical University Innsbruck, Innsbruck, Austria. klaus.seppi@uki.at</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Weintraub</LastName>
<ForeName>Daniel</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y"><LastName>Coelho</LastName>
<ForeName>Miguel</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Perez-Lloret</LastName>
<ForeName>Santiago</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Fox</LastName>
<ForeName>Susan H</ForeName>
<Initials>SH</Initials>
</Author>
<Author ValidYN="Y"><LastName>Katzenschlager</LastName>
<ForeName>Regina</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y"><LastName>Hametner</LastName>
<ForeName>Eva-Maria</ForeName>
<Initials>EM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Poewe</LastName>
<ForeName>Werner</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y"><LastName>Rascol</LastName>
<ForeName>Olivier</ForeName>
<Initials>O</Initials>
</Author>
<Author ValidYN="Y"><LastName>Goetz</LastName>
<ForeName>Christopher G</ForeName>
<Initials>CG</Initials>
</Author>
<Author ValidYN="Y"><LastName>Sampaio</LastName>
<ForeName>Cristina</ForeName>
<Initials>C</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>P50 NS053488</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2010 Apr 13;74(15):1203-7</RefSource>
<PMID Version="1">20385892</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2010 May;16(4):298-300</RefSource>
<PMID Version="1">19864172</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2010 Apr 30;25(6):790-1</RefSource>
<PMID Version="1">20198646</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2010 Apr 30;25(6):704-9</RefSource>
<PMID Version="1">20437539</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Neurol. 2010 Jun;9(6):573-80</RefSource>
<PMID Version="1">20452823</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cochrane Database Syst Rev. 2010;(7):CD007570</RefSource>
<PMID Version="1">20614462</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2010 Aug 3;75(5):448-55</RefSource>
<PMID Version="1">20679638</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Sleep Med. 2010 Sep;11(8):759-65</RefSource>
<PMID Version="1">20674489</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2010 Aug 15;25(11):1708-14</RefSource>
<PMID Version="1">20589875</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2010 Sep;68(3):400-4</RefSource>
<PMID Version="1">20687121</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Pharmacother. 2010 Oct;44(10):1624-32</RefSource>
<PMID Version="1">20736422</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Neurol. 2010 Oct;9(10):969-77</RefSource>
<PMID Version="1">20729148</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Impot Res. 2010 Sep-Oct;22(5):325-35</RefSource>
<PMID Version="1">20861846</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2010 Oct 30;25(14):2311-7</RefSource>
<PMID Version="1">20740485</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2010 Dec;68(6):963-8</RefSource>
<PMID Version="1">21154480</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2011 Jan;26(1):90-9</RefSource>
<PMID Version="1">21322021</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 1997 Apr;48(4):1070-7</RefSource>
<PMID Version="1">9109902</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 1997 Oct;49(4):1168-70</RefSource>
<PMID Version="1">9339713</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Psychiatry. 1998;59 Suppl 3:3-7</RefSource>
<PMID Version="1">9541331</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurol. 1998 May;245 Suppl 1:S15-8</RefSource>
<PMID Version="1">9617717</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Am Pharm Assoc (Wash). 1999 Jul-Aug;39(4):526-30</RefSource>
<PMID Version="1">10467818</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2004 Dec 9;351(24):2509-18</RefSource>
<PMID Version="1">15590953</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Evid Rep Technol Assess (Summ). 2004 Nov;(108):1-7</RefSource>
<PMID Version="1">15635761</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2005 Feb;20(2):190-9</RefSource>
<PMID Version="1">15551331</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2005 Apr 26;64(8):1450-1</RefSource>
<PMID Version="1">15851743</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2005 May;20(5):523-39</RefSource>
<PMID Version="1">15818599</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Curr Med Res Opin. 2005 Jan;21(1):1-10</RefSource>
<PMID Version="1">15881470</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2005 Jul;76(7):934-9</RefSource>
<PMID Version="1">15965198</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2005 Aug;20(8):958-63</RefSource>
<PMID Version="1">15800937</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2005 Sep;20(9):1161-9</RefSource>
<PMID Version="1">15954137</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Sleep Med. 2005 Sep;6(5):459-66</RefSource>
<PMID Version="1">16084125</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2005 Dec;76(12):1636-9</RefSource>
<PMID Version="1">16291885</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2006 Jan;21(1):115-6</RefSource>
<PMID Version="1">16142776</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Gen Intern Med. 2005 Dec;20(12):1151-8</RefSource>
<PMID Version="1">16423108</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain Res Bull. 2006 Feb 15;68(6):393-405</RefSource>
<PMID Version="1">16459193</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Clin Pract Urol. 2005 May;2(5):239-47</RefSource>
<PMID Version="1">16474835</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Pharmacol. 2006 Mar 8;533(1-3):36-9</RefSource>
<PMID Version="1">16488410</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2006 Apr 11;66(7):996-1002</RefSource>
<PMID Version="1">16606910</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cochrane Database Syst Rev. 2006;(2):CD003154</RefSource>
<PMID Version="1">16625572</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2006 May;21(5):704-7</RefSource>
<PMID Version="1">16440332</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurol. 2006 May;253(5):601-7</RefSource>
<PMID Version="1">16607468</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Neurol. 2006 Sep;13(9):930-6</RefSource>
<PMID Version="1">16930356</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2006 Jul;21(7):916-23</RefSource>
<PMID Version="1">16547944</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Pharmacother. 2006 Sep;40(9):1618-22</RefSource>
<PMID Version="1">16896026</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2006 Aug;21(8):1119-22</RefSource>
<PMID Version="1">16637039</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Neuropharmacol. 2006 Nov-Dec;29(6):331-7</RefSource>
<PMID Version="1">17095896</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurol. 2006 Dec;253 Suppl 7:VII2-6</RefSource>
<PMID Version="1">17131223</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2007 Jan;22(1):41-7</RefSource>
<PMID Version="1">17115387</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2007 Feb 15;22(3):313-8</RefSource>
<PMID Version="1">17034006</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurol. 2007 Apr;254(4):459-64</RefSource>
<PMID Version="1">17404779</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2007 Jun 15;22(8):1061-8</RefSource>
<PMID Version="1">17266092</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2007 Jul 15;22(9):1215-6</RefSource>
<PMID Version="1">17557344</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2007 Jul 15;22(9):1239-44</RefSource>
<PMID Version="1">17566120</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2007 Aug 15;22(11):1543-9</RefSource>
<PMID Version="1">17557339</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2007 Oct 15;22(13):1901-11</RefSource>
<PMID Version="1">17674410</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2007 Oct 31;22(14):2070-6</RefSource>
<PMID Version="1">17674415</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2007 Dec;13(8):532-4</RefSource>
<PMID Version="1">17383926</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Interv Aging. 2007;2(3):313-26</RefSource>
<PMID Version="1">18044182</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2007 Nov 15;22(15):2268-73</RefSource>
<PMID Version="1">17876852</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2007 Dec;22(16):2314-24</RefSource>
<PMID Version="1">18098298</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2008;14(2):166-9</RefSource>
<PMID Version="1">17509924</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neuropsychol Rev. 2008 Mar;18(1):103-19</RefSource>
<PMID Version="1">18322801</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2008 Apr 30;23(6):850-7</RefSource>
<PMID Version="1">18311826</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2008 May 6;70(19):1707-14</RefSource>
<PMID Version="1">18458231</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Affect Disord. 2008 Dec;111(2-3):351-9</RefSource>
<PMID Version="1">18485485</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurosci Behav Physiol. 2008 Nov;38(9):937-45</RefSource>
<PMID Version="1">18975103</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2008 Nov 15;23(15):2129-70</RefSource>
<PMID Version="1">19025984</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pharmacol Res. 2009 Jan;59(1):1-12</RefSource>
<PMID Version="1">18977443</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2008 Dec;64 Suppl 2:S81-92</RefSource>
<PMID Version="1">19127578</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2009 Mar 10;72(10):886-92</RefSource>
<PMID Version="1">19092112</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurol. 2009 Apr;256(4):563-7</RefSource>
<PMID Version="1">19401804</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Neurol. 2009 Jul;8(7):613-8</RefSource>
<PMID Version="1">19520613</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2009 Jun 15;24(8):1217-21</RefSource>
<PMID Version="1">19370737</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Neurosci. 2009;119(12):2196-205</RefSource>
<PMID Version="1">19916848</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Neuropharmacol. 2009 Nov-Dec;32(6):305-10</RefSource>
<PMID Version="1">19620846</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>JAMA. 2010 Jan 6;303(1):47-53</RefSource>
<PMID Version="1">20051569</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Psychopharmacology (Berl). 2010 Jan;207(4):593-7</RefSource>
<PMID Version="1">19823807</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2010;25 Suppl 1:S123-30</RefSource>
<PMID Version="1">20187234</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurol. 2010 Mar;257(3):452-6</RefSource>
<PMID Version="1">19842011</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2010 Mar 16;74(11):924-31</RefSource>
<PMID Version="1">20231670</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2000 Oct 24;55(8):1216-8</RefSource>
<PMID Version="1">11071504</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2001 Jan;16(1):135-9</RefSource>
<PMID Version="1">11215574</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2001 Sep;71(3):371-4</RefSource>
<PMID Version="1">11511713</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2002 Jun;72(6):708-12</RefSource>
<PMID Version="1">12023410</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2002 Aug 13;59(3):408-13</RefSource>
<PMID Version="1">12177375</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2002 Jul;17(4):676-81</RefSource>
<PMID Version="1">12210856</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Biol Psychiatry. 2002 Sep 1;52(5):438-45</RefSource>
<PMID Version="1">12242060</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2002 Sep;17(5):1031-5</RefSource>
<PMID Version="1">12360554</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Sleep. 2002 Dec15;25(8):905-9</RefSource>
<PMID Version="1">12489899</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Rev Neurol. 2002 Dec 1-15;35(11):1010-4</RefSource>
<PMID Version="1">12497304</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2003 Mar;18(3):287-93</RefSource>
<PMID Version="1">12621632</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2003 May;18(5):510-4</RefSource>
<PMID Version="1">12722164</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2003 Jun;18(6):685-8</RefSource>
<PMID Version="1">12784273</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Geriatr Psychiatry. 2003 Jun;18(6):552-4</RefSource>
<PMID Version="1">12789682</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Neurol. 2003 Jul;10(4):399-406</RefSource>
<PMID Version="1">12823492</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2003 Sep;18 Suppl 6:S80-7</RefSource>
<PMID Version="1">14502660</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Psychopharmacol. 2003 Oct;23(5):509-13</RefSource>
<PMID Version="1">14520130</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2003 Nov 11;61(9):1279-81</RefSource>
<PMID Version="1">14610139</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Geriatr Psychiatry. 2004 Jan;19(1):1-8</RefSource>
<PMID Version="1">14716693</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2004 Jan 13;62(1):37-40</RefSource>
<PMID Version="1">14718694</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Neurol Neurosurg. 2004 Mar;106(2):93-6</RefSource>
<PMID Version="1">15003297</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2004 May;75(5):689-95</RefSource>
<PMID Version="1">15090561</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am Fam Physician. 2004 Jun 1;69(11):2628-34</RefSource>
<PMID Version="1">15202698</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2004 Aug;75(8):1171-4</RefSource>
<PMID Version="1">15258224</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Neuropharmacol. 2004 Jul-Aug;27(4):153-6</RefSource>
<PMID Version="1">15319699</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain. 1983 Jun;106 (Pt 2):257-70</RefSource>
<PMID Version="1">6850270</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Affect Disord. 1983 May;5(2):141-5</RefSource>
<PMID Version="1">6222093</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 1995 Sep;45(9):1757-60</RefSource>
<PMID Version="1">7675241</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Pediatr Adolesc Med. 1996 Sep;150(9):932-5</RefSource>
<PMID Version="1">8790123</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Psychiatry. 1996 Oct;57(10):449-54</RefSource>
<PMID Version="1">8909330</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D001342">Autonomic Nervous System Diseases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D003072">Cognition Disorders</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="Y" UI="D019317">Evidence-Based Medicine</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D001523">Mental Disorders</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D019964">Mood Disorders</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D011619">Psychotropic Drugs</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D016032">Randomized Controlled Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D020919">Sleep Disorders, Intrinsic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS573403</OtherID>
<OtherID Source="NLM">PMC4020145</OtherID>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year>
<Month>10</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2011</Year>
<Month>11</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2012</Year>
<Month>3</Month>
<Day>1</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="doi">10.1002/mds.23884</ArticleId>
<ArticleId IdType="pubmed">22021174</ArticleId>
<ArticleId IdType="pmc">PMC4020145</ArticleId>
<ArticleId IdType="mid">NIHMS573403</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F73 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000F73 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:22021174 |texte= The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:22021174" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
![]() | This area was generated with Dilib version V0.6.23. | ![]() |